There are currently 441 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
NCT06855654
Recruiting
This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in the Promoting Resilience in Women with Breast Cancer (PRISM) intervention, overall and stratified by race, and to evaluate the feasibility and acceptability of the PRISM intervention in the MBC population. Black women with MBC have shorter survival from the time of meta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: The University of Alabama, Birmingham, Alabama +1 locations
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT05608252
Recruiting
This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Register for Updates
F-Tryptophan PET/CT in Human Cancers
NCT05556473
Recruiting
Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Intracranial Glioma, Metastatic Brain Tumor, Breast Cancer, Neuroendocrine Tumors, Rectal Cancer
Register for Updates
Exercise in Metastatic Breast Cancer: EMBody
NCT05468034
Recruiting
The purpose of this study is to study exercise in a novel population with indolent MBC (no progression on current therapy in prior 12 months and not receiving cytotoxic chemotherapy). The study team hypothesizes that delivering virtual, supervised, progressive intensity aerobic and resistance training exercise for 16 weeks in this population will significantly improve 1) cardiorespiratory fitness, functional status, and sarcopenia (low muscle mass), all established predictors of survival, and 2)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Yale Cancer Center, New Haven, Connecticut +5 locations
Conditions: Breast Cancer, Indolent Metastatic Breast Cancer
Register for Updates
The COMPASSION Study
NCT06507930
Recruiting
The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Breast Carcinoma
Register for Updates
NearWave Optical Molecular Monitoring
NCT06744465
Recruiting
The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvant chemotherapy (NAC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Breast Cancer, HER2-positive Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Carcinoma
Register for Updates
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT05020860
Recruiting
The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Harris Health System - Smith Clinic, Houston, Texas +1 locations
Conditions: Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
Register for Updates
Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT04998682
Recruiting
The purpose of this research is to evaluate how to manage the axillary lymph nodes in patients with breast cancer. The investigators will determine if a sampling of the lymph nodes under the arm will give the information necessary to determine if fewer lymph nodes can be removed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer
Register for Updates
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692
Recruiting
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Arizona Oncology Associates, Tucson, Arizona +8 locations
Conditions: Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
Register for Updates
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT04683679
Recruiting
The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radiation therapy alone).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Register for Updates
COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients
NCT05972343
Recruiting
This is a subject registry study of patients who undergo cryoablation for their breast cancer after being determined not to be surgical candidates. Data collected as part of this registry will be used to assess the safety of percutaneous ultrasound-guided cryoablation in this population as well as provide long-term follow-up of subjects who received cryoablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Cancer, Cancer of the Breast
Register for Updates
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
NCT05921253
Recruiting
This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.
Gender:
ALL
Ages:
Between 50 years and 99 years
Trial Updated:
02/21/2025
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma +1 locations
Conditions: Breast Cancer, Lymphoma
Register for Updates